Vikram Paranjpe1, Jeremy Tan2, Jason Nguyen3, John Lee1, Jeremy Allegood4, Anat Galor5, Nawajes Mandal6. 1. Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL, 33125, USA; Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA. 2. Ophthalmic Surgeons and Consultants of Ohio, Ohio State University, Columbus, OH, 43203, USA. 3. West Virginia University Eye, Morgantown, WV, 26506, USA. 4. Lipidomics Core, Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, VA, 23249, USA. 5. Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL, 33125, USA; Bascom Palmer Eye Institute, University of Miami, 900 NW 17th Street, Miami, FL, 33136, USA. Electronic address: agalor@med.miami.edu. 6. Department of Ophthalmology, Anatomy and Neurobiology, University of Tennessee Health Sciences Center, Hamilton Eye Institute, 930 Madison Avenue, Memphis, TN, 38163, USA. Electronic address: nmandal@uthsc.edu.
Abstract
PURPOSE: Sphingolipids (SPL) play roles in cell signaling, inflammation, and apoptosis. Changes in SPL composition have been reported in individuals with MGD, but associations between clinical signs of MGD and compositional changes in meibum SPLs have not been examined. METHODS: Forty-three individuals underwent a tear film assessment. Groups were split into those with good or poor quality meibum. Meibum was collected then analyzed with liquid chromatography-mass spectroscopy to quantify SPL classes. Relative composition of SPL and major classes, Ceramide (Cer), Hexosyl-Ceramide (Hex-Cer), Sphingomyelin (SM), Sphingosine (Sph) and Sphingosine 1-phosphate (S1P) was calculated via mole percent. RESULTS: 22 and 21 individuals were characterized with good and poor quality meibum, respectively. Individuals with poor quality were older (60 ± 8 vs 51 ± 16 years) and more likely to be male (90% vs 64%). Relative composition analysis revealed that individuals with poor meibum quality had SPL composed of less Cer (33.36% vs 49.49%, p < 0.01), Hex-Cer (4.88% vs 9.15%, p < 0.01), and S1P (0.16% vs 0.31%, p = 0.05), and more SM (58.67% vs 38.18%, p < 0.01) and Sph (2.92% vs 2.87%, p = 0.97) compared to individuals with good quality meibum. Assessment of the ratio of Cer (pro-apoptotic) to S1P (pro-survival) showed that individuals with poor meibum quality had a relative increase in Cer (495.23 vs 282.69, p = 0.07). CONCLUSION: Meibum quality, a clinically graded marker of MGD, is associated with compositional changes in meibum sphingolipids. Further investigation of the structural and bioactive roles of sphingolipids in MGD may provide future targets for therapy.
PURPOSE: Sphingolipids (SPL) play roles in cell signaling, inflammation, and apoptosis. Changes in SPL composition have been reported in individuals with MGD, but associations between clinical signs of MGD and compositional changes in meibum SPLs have not been examined. METHODS: Forty-three individuals underwent a tear film assessment. Groups were split into those with good or poor quality meibum. Meibum was collected then analyzed with liquid chromatography-mass spectroscopy to quantify SPL classes. Relative composition of SPL and major classes, Ceramide (Cer), Hexosyl-Ceramide (Hex-Cer), Sphingomyelin (SM), Sphingosine (Sph) and Sphingosine 1-phosphate (S1P) was calculated via mole percent. RESULTS: 22 and 21 individuals were characterized with good and poor quality meibum, respectively. Individuals with poor quality were older (60 ± 8 vs 51 ± 16 years) and more likely to be male (90% vs 64%). Relative composition analysis revealed that individuals with poor meibum quality had SPL composed of less Cer (33.36% vs 49.49%, p < 0.01), Hex-Cer (4.88% vs 9.15%, p < 0.01), and S1P (0.16% vs 0.31%, p = 0.05), and more SM (58.67% vs 38.18%, p < 0.01) and Sph (2.92% vs 2.87%, p = 0.97) compared to individuals with good quality meibum. Assessment of the ratio of Cer (pro-apoptotic) to S1P (pro-survival) showed that individuals with poor meibum quality had a relative increase in Cer (495.23 vs 282.69, p = 0.07). CONCLUSION: Meibum quality, a clinically graded marker of MGD, is associated with compositional changes in meibum sphingolipids. Further investigation of the structural and bioactive roles of sphingolipids in MGD may provide future targets for therapy.
Authors: Nitai C Hait; Laura E Wise; Jeremy C Allegood; Megan O'Brien; Dorit Avni; Thomas M Reeves; Pamela E Knapp; Junyan Lu; Cheng Luo; Michael F Miles; Sheldon Milstien; Aron H Lichtman; Sarah Spiegel Journal: Nat Neurosci Date: 2014-05-25 Impact factor: 24.884
Authors: Hui Qi; Shrestha Priyadarsini; Sarah E Nicholas; Akhee Sarker-Nag; Jeremy Allegood; Charles E Chalfant; Nawajes A Mandal; Dimitrios Karamichos Journal: J Lipid Res Date: 2017-02-10 Impact factor: 5.922
Authors: Richard S Brush; Julie-Thu A Tran; Kimberly R Henry; Mark E McClellan; Michael H Elliott; Md Nawajes A Mandal Journal: Invest Ophthalmol Vis Sci Date: 2010-04-14 Impact factor: 4.799
Authors: Dayanjan S Wijesinghe; Matthew Brentnall; Jennifer A Mietla; L Alexis Hoeferlin; Robert F Diegelmann; Lawrence H Boise; Charles E Chalfant Journal: J Lipid Res Date: 2014-05-13 Impact factor: 5.922
Authors: Koushik Mondal; Haruka Takahashi; Jerome Cole; Nobel A Del Mar; Chunyan Li; Daniel J Stephenson; Jeremy Allegood; L Ashley Cowart; Charles E Chalfant; Anton Reiner; Nawajes Mandal Journal: Mol Neurobiol Date: 2021-08-08 Impact factor: 5.590